34
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Management of non-small-cell lung cancer: recent developments.

      Lancet
      Antineoplastic Agents, therapeutic use, Carcinoma, Non-Small-Cell Lung, genetics, pathology, therapy, Chemotherapy, Adjuvant, trends, Diagnostic Imaging, Early Detection of Cancer, Forecasting, Humans, Individualized Medicine, Lung Neoplasms, Medical Oncology, standards, Neoplasm Metastasis, Neoplasm Staging, Quality of Health Care, Radiotherapy, Adjuvant, Receptor, Epidermal Growth Factor, antagonists & inhibitors

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Non-small-cell lung cancer is one of the leading causes of deaths from cancer worldwide. Therefore, improvements in diagnostics and treatments are urgently needed. In this review, we will discuss the evolution of lung cancer staging towards more non-invasive, endoscopy-based, and image-based methods, and the development of stage-adapted treatment. A special focus will be placed on the role of novel surgical approaches and modern radiotherapy strategies for early stages of disease, the effect of multimodal treatment in locally advanced disease, and ongoing developments in the treatment of patients with metastatic disease. In particular, we will include an emphasis on targeted therapies, which are based on the assumption that a treatable driver mutation or gene rearrangement is present within the tumour. Finally, the position of lung cancer treatment on the pathway to personalised therapy will be discussed. Copyright © 2013 Elsevier Ltd. All rights reserved.

          Related collections

          Author and article information

          Comments

          Comment on this article